vendredi 1 septembre 2017

Onco Actu du 1er septembre 2017

1. Biologie

US scientists share research of children’s cancers to accelerate progress [Cancer Research UK]

3.3 Prévention - Vaccins

Why HPV Vaccination Rates Remain Low in Rural States [MIT Technology Review]

4.9 Dép., diag. & prono. - Sein

Three questions to ask about calls to widen breast cancer screening [The Conversation]

5. Traitements

Updated ESMO Magnitude of Clinical Benefit Scale Set to Evaluate Single-arm Studies [ESMO]

Bringing the Investigational Breast Cancer Drug Endoxifen from Bench to Bedside with NCI Support [NCI]

Of mice and men: why animal trial results don’t always translate to humans [The Conversation]

Microscopic lasers may stop tumours spreading around the body [The Economist]

Hormone Treatment for Prostate Cancer Tied to Heart Risks [NY Times]

5.12 Immunothérapies

As cancer patients look to last-chance therapies, hard conversations are getting postponed [STAT]

5.12.3 Immunothérapies-combinaisons

Early Keytruda combo data paint Incyte’s epacadostat as a threat to Bristol-Myers’ I-O melanoma franchise [FierceBiotech]

Lessons Learned From Combining Anti-OX40 and Anti-PD1 Immunotherapies [Cancer Research Catalyst]

5.12.6 Immunothérapies - AMM

Novartis: CAR-T Results In One Month, Or No Charge. Why One Month? [Xconomy]

FDA Approves First CAR T-cell Therapy [Cancer Research Catalyst]

5.12.8 Immunothérapies - Economie

Profit on $475,000 Novartis cancer drug could be a while coming [Reuters]

5.2.2 Pharma - Fusions & Acquisitions

AstraZeneca's M&A Daydreams [Bloomberg]

Daiichi Sankyo douses a puzzling report about an AstraZeneca buyout offer [EndPoints]

Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca [Reuters]

5.3 Traitements - FDA, EMA, NICE...

EMA Opens Consultations of Two Revised ICH Guidelines [RAPS]

Novartis, UCSF researchers urge FDA to clean up its messy adverse events database [EndPoints]

Statement from Center for Drug Evaluation and Research Director Janet Woodcock regarding safety concerns related to investigational use of Keytruda in multiple myeloma [FDA]

5.6 ESMO

New and Updated Data for KEYTRUDA® (pembrolizumab) from Merck’s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress [Merck]

Puma Biotechnology Announces Publication of Abstracts for ESMO 2017 [Puma]

Bayer to showcase latest oncology research at ESMO 2017 [Bayer]

Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress [Roche]

AstraZeneca aims to offset drug setback at big cancer congress [Reuters]

6.1 Observation

Many People Can Delay Treatment For Thyroid Cancer, Study Finds [NPR]